Drugs targeting androgen receptor activity promote development of a neuroendocrine prostate cancer phenotype (5) and increases the prevalence of neuroendocrine cells (6), and as more drugs in this category reach the clinic the occurrence is expected to rise. This evidence concerns the gene AR and prostate carcinoma.